Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   - « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Zona, Margherita
NCT04995133: Colistin Intravenous Administration in Critically Ill Patients Suffering From Hospital Infections Caused by Multi-antibiotic-resistant Germs.	Recruiting	4	20	Europe	Colistin	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	Hospital Infection, Multi-antibiotic Resistance, Critically Ill	01/22	01/22
THUNDER2, NCT04815694: THeragnostic Utilities for Neoplastic DisEases of the Rectum by MRI Guided Radiotherapy	Recruiting	N/A	63	Europe	RT Dose escalation in LARC patients with an Early Regression Index > 13.1 at second week on nCRT	Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Viewray Inc.	Neoadjuvant Chemoradiotherapy, Locally Advanced Rectal Cancer, Pathological Complete Response	03/22	09/22

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Zona, Margherita
NCT04995133: Colistin Intravenous Administration in Critically Ill Patients Suffering From Hospital Infections Caused by Multi-antibiotic-resistant Germs.	Recruiting	4	20	Europe	Colistin	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	Hospital Infection, Multi-antibiotic Resistance, Critically Ill	01/22	01/22
THUNDER2, NCT04815694: THeragnostic Utilities for Neoplastic DisEases of the Rectum by MRI Guided Radiotherapy	Recruiting	N/A	63	Europe	RT Dose escalation in LARC patients with an Early Regression Index > 13.1 at second week on nCRT	Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Viewray Inc.	Neoadjuvant Chemoradiotherapy, Locally Advanced Rectal Cancer, Pathological Complete Response	03/22	09/22